,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['trastuzumab', 'bcsm', 'breast']
this is a great summary of the much awaited #asco22 plenary tomorrow on trastuzumab deruxtecan (t-dxd) in her-2 low #breastcancer.
#pathologists should pay attention as these data will redefine how her-2 status is determined, especially if there are differences in 1+ v 2+. #bcsm 
Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer.